N-Acetylcysteine Supplementation

Current understanding

N-acetylcysteine (NAC) is an antioxidant/glutathione precursor under early clinical investigation in MPN, with a phase I/II dose-finding trial now underway [mpn-direct, trial-early]. The mechanistic rationale rests on reducing oxidative stress and JAK2-driven ROS signaling [mechanism-plausible — biology suggests NAC could blunt clonal oxidative damage but no completed MPN study confirms clinical benefit]. No efficacy or safety conclusions are yet available; optimal dose, target population, and outcome impact remain open.

Evidence log

• 2026-03-10 — An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms: cross-connection with curcumin-supplementation: Both are supplement/antioxidant interventions in active MPN trials targeting inflammation/oxidative-stress pathways; useful to track in parallel as the early antioxidant-supplement evidence base for MPN. (novelty: 3)

Open questions

Related